Marion Wobser

ORCID: 0000-0002-6293-2554
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cutaneous lymphoproliferative disorders research
  • Lymphoma Diagnosis and Treatment
  • Nail Diseases and Treatments
  • Fungal Infections and Studies
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • CNS Lymphoma Diagnosis and Treatment
  • Autoimmune Bullous Skin Diseases
  • Vascular Tumors and Angiosarcomas
  • T-cell and Retrovirus Studies
  • Genetic and rare skin diseases.
  • Eosinophilic Disorders and Syndromes
  • Tumors and Oncological Cases
  • Antenna Design and Analysis
  • Immunotherapy and Immune Responses
  • Sarcoma Diagnosis and Treatment
  • Dermatological and Skeletal Disorders
  • Polyomavirus and related diseases
  • Cancer and Skin Lesions
  • Ocular Oncology and Treatments
  • Toxin Mechanisms and Immunotoxins
  • Full-Duplex Wireless Communications
  • Skin and Cellular Biology Research
  • Melanoma and MAPK Pathways
  • Soft tissue tumor case studies

Universitätsklinikum Würzburg
2016-2025

Austrian Society of Dermatology and Venereology
2016-2025

Universitäts-Kinderklinik Würzburg
2023

Comprehensive Cancer Center Mainfranken
2014-2021

John Wiley & Sons (United States)
2021

John Wiley & Sons (United Kingdom)
2021

University of Würzburg
2010-2021

Oxfam
2021

Hudson Institute
2021

European Organisation for Research and Treatment of Cancer
2018

10.1016/s0140-6736(17)31266-7 article EN The Lancet 2017-06-07
Julia Scarisbrick Pietro Quaglino H. Miles Prince Evangelia Papadavid Emmilia Hodak and 95 more M. Bagot Octavio Servitje Emilio Berti Pablo L. Ortiz‐Romero Rudolf Stadler Aikaterini Patsatsi Robert Knobler Emmanuella Guenova Fiona Child Sean Whittaker Vasiliki Nikolaou Carlo Tomasini Iris Amitay Hadas Prag Naveh C. Ram‐Wolff Maxime Battistella Silvia Alberti Violetti R. Stranzenbach Vanessa Gargallo Cristina Muniesa Triantafyllia Κoletsa Constanze Jonak Stefanie Porkert Christina Mitteldorf Teresa Estrach Andrea Combalía Márta Marschalkó Judit Csomor Ágota Szepesi Antonio Cozzio Reinhard Dummer Nicola Pimpinelli Vieri Grandi M. Beylot‐Barry Anne Pham‐Ledard Marion Wobser Eva Geissinger Ulrike Wehkamp Michael Weichenthal Richard Cowan Eileen Parry Jeremy P. Harris Rachel Wachsmuth Deborah Turner Andrew Bates Eugene Healy Franz Trautinger Johanna Latzka Jungmin Yoo B. Vydianath Rasoul Amel-Kashipaz Leonidas Marinos A. Oikonomidi Alexander J. Stratigos Marie‐Dominique Vignon‐Pennamen Maxime Battistella Fina Climent Eva González‐Barca Elisavet Georgiou Rebecca Senetta Pier Luigi Zinzani Liisa Väkevä Annamari Ranki A.M. Busschots Esther Hauben An Bervoets F. J. Sherida H. Woei‐A‐Jin Rubeta Matin Graham P. Collins Sophie Weatherhead J. Frew M. Bayne Giles Dunnill Pam McKay Arvind Arumainathan Richard Azurdia Kim Benstead Robert Twigger Kerri E. Rieger Ryanne A. Brown José Antônio Sanches Denis Miyashiro Oleg E. Akilov Sue McCann Helka Sahi Fabiana Damasco Christiane Querfeld Amy Folkes Cecilia Bur C.‐D. Klemke Paula Enz Ramón M. Pujol Koen D. Quint Larisa J. Geskin Eric Hong

Survival in mycosis fungoides (MF) is varied and may be poor. The PROCLIPI (PROspective Cutaneous Lymphoma International Prognostic Index) study a web-based data collection system for early-stage MF with legal data-sharing agreements permitting international collaboration rare cancer complex pathology. Clinicopathological must 100% complete in-built intelligence the database ensures accurate staging.

10.1111/bjd.17258 article EN British Journal of Dermatology 2018-09-29

Common birthmarks can be an indicator of underlying genetic disease but are often overlooked. Mongolian blue spots (dermal melanocytosis) usually localized and transient, they extensive, permanent, associated with extracutaneous abnormalities. Co-occurrence vascular defines a subtype phakomatosis pigmentovascularis, group syndromes neurovascular, ophthalmological, overgrowth, malignant complications. Here, we discover that extensive dermal melanocytosis pigmentovascularis activating...

10.1016/j.jid.2015.11.027 article EN cc-by Journal of Investigative Dermatology 2016-01-14

The pocket protein (PP) family consists of the three members RB1, p107 and p130 all possessing tumor suppressive properties. Indeed, PPs jointly control G1/S transition mainly by inhibiting E2F transcription factors. Notably, several viral oncoproteins are capable binding PPs. Merkel cell polyomavirus (MCPyV) is considered as etiological factor for carcinoma (MCC) with expression Large T antigen (LT) harboring an intact PP domain being required proliferation most MCC cells. Therefore, we...

10.18632/oncotarget.8793 article EN Oncotarget 2016-04-18

Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common cutaneous T-cell lymphomas. MF/SS is accompanied by considerable morbidity from pain, itching disfigurement.To identify factors associated with poorer health-related quality of life (HRQoL) in patients newly diagnosed MF/SS.Patients enrolled into Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI; an international observational study MF/SS) had their HRQoL assessed using Skindex-29 questionnaire. scores...

10.1111/bjd.18089 article EN British Journal of Dermatology 2019-05-03

Abstract The transcription factor NRF2 is the major mediator of oxidative stress responses and closely connected to therapy resistance in tumors harboring activating mutations pathway. In melanoma, such are rare, it unclear what extent melanomas rely on NRF2. Here we show that suppresses activity melanocyte lineage marker MITF thereby reducing expression pigmentation markers. Intriguingly, furthermore identified as key regulator immune-modulating genes, linking with induction cyclooxygenase...

10.1038/s41388-020-01477-8 article EN cc-by Oncogene 2020-09-25

Cutaneous lymphomas (CL) are categorized as extranodal non-Hodgkin lymphomas, constituting the second most common form in this group (MALT of stomach form). Their incidence is estimated at one new diagnosis per 100,000 inhabitants year Germany [1-3]. Primary CL, by definition, present skin first, and time after staging completed do not show any involvement other organs. Secondary on hand, cutaneous manifestations disseminated [4], primarily nodal or leukemias. CL comprise a large, clinically...

10.1111/ddg.14706 article EN JDDG Journal der Deutschen Dermatologischen Gesellschaft 2022-04-01

Patients with Sézary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), are prone to Staphylococcus aureus infections and have poor prognosis due treatment resistance. Here, we report that S staphylococcal enterotoxins (SE) induce drug resistance in malignant T cells against therapeutics commonly used CTCL. Supernatant from patient-derived, SE-producing recombinant SE significantly inhibit cell death induced by histone deacetylase (HDAC) inhibitor romidepsin primary...

10.1182/blood.2023021671 article EN cc-by-nc-nd Blood 2024-01-03

The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality life (QoL) in patients with newly diagnosed mycosis fungoides (MF).

10.1111/bjd.19252 article EN British Journal of Dermatology 2020-06-01

Abstract Targeted therapies for cutaneous T-cell lymphoma (CTCL) are limited and curative approaches lacking. Furthermore, relapses drug induced side effects major challenges in the therapeutic management of patients with CTCL, creating an urgent need new effective therapies. Pathologic constitutive NF-κB activity leads to apoptosis resistance CTCL cells and, thus, represents a promising target CTCL. In preclinical study we showed potential dimethyl fumarate (DMF) block specifically, kill...

10.1182/blood.2022018669 article EN cc-by-nc-nd Blood 2023-05-22

Therapeutic vaccination directed to induce an anti-tumoral T-cell response is a field of extensive investigation in the treatment melanoma. However, many trials melanoma failed demonstrate correlation between vaccine-specific immune and therapy outcome. This has been mainly attributed escape by antigen loss, rendering us need new targets.This phase-II trial investigated peptide against survivin, oncogenic inhibitor-of-apoptosis protein crucial for survival tumor cells,...

10.1007/s00262-012-1266-9 article EN cc-by Cancer Immunology Immunotherapy 2012-05-07

Indolent cutaneous CD8+ lymphoid proliferation is a recently described rare entity among T-cell lymphomas that typically presents with solitary skin lesions at acral sites. Separation from otherwise aggressive bearing cytotoxic phenotype fundamental to avoid unnecessary harmful treatment. However, up now, no reliable discriminative marker has been identified.Motivated by these diagnostic quandaries, we have analyzed large series of archived formalin-fixed paraffin-embedded (FFPE) specimens...

10.1111/bjd.13628 article EN British Journal of Dermatology 2014-12-19

Pleomorphic dermal sarcomas (PDS) are frequent UV-induced of the skin intermediate grade malignant potential. Despite fact that PDS have a noteworthy potential to recur (up 28%) as well metastasize 20%), there no specific clinical guidelines with respect follow-up these patients. Moreover, little is known about clinical, histological or molecular prognostic factors in PDS.The aim present study was identify risk predict relapse large multicentre sample cohort which could aid optimize...

10.1111/jdv.15493 article EN Journal of the European Academy of Dermatology and Venereology 2019-02-15

The differential diagnosis of atypical dermal nonepidermotropic CD8+ lymphocytic infiltrates includes a heterogeneous spectrum lymphoproliferations with overlapping histological and phenotypic features, but divergent clinical manifestations prognoses. As these neoplasms are rare, more data on their clinicopathological presentation course needed.To assess the clinical, immunophenotypic features; outcomes of; differences between lymphoproliferations.Retrospective analysis series 46 patients...

10.1111/bjd.20973 article EN British Journal of Dermatology 2022-01-06

Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL). However, there a need for further improvement of this therapeutic approach. Here, we compared the mode action romidepsin (FK228), an established class I histone deacetylase inhibitor, and domatinostat (4SC-202), novel inhibitor HDACs, which has been reported to also target lysine-specific demethylase 1A (LSD1). We performed MTS assays flow cytometric analyses propidium iodide or annexin V-stained cells assess...

10.1186/s13045-019-0719-4 article EN cc-by Journal of Hematology & Oncology 2019-03-18

Kutane Lymphome (cutaneous lymphomas; CL) gehören zur Gruppe der extranodalen Non-Hodgkin-Lymphome, innerhalb derer sie die zweithäufigste Form darstellen (Magen-MALT-Lymphome sind häufigste extranodale Form). Die Inzidenz wird auf eine Neuerkrankung pro Jahr und 100 000 Einwohner geschätzt [1-3]. Primäre CL manifestieren sich definitionsgemäß zunächst in Haut zeigen zum Zeitpunkt Diagnosestellung nach abgeschlossener Ausbreitungsdiagnostik (Staging) keine weitere Organbeteiligung, während...

10.1111/ddg.14706_g article DE cc-by-nc-nd JDDG Journal der Deutschen Dermatologischen Gesellschaft 2022-04-01
Coming Soon ...